SCHEMBL2156935

SCHEMBL2156935

Cc1ccc2c(c1)SCC(CO)(CO)C2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
EPHX2 P34913 1/20 0.40
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
ATM Q13315 1/20 0.35
ACHE P22303 2/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
DGAT1 O75907 1/20 0.32
ELANE P08246 1/20 0.32
LCK P06239 1/20 0.31
METAP1 P53582 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155997 0.78 MAPT (0.44) KDM4EALDH1A1HPGDHTTACHE
SCHEMBL13535009 0.75 CA1 (0.39) CA1CA2CA4CA7CA9
SCHEMBL2157042 0.70 LMNA (0.43) KDM4EALDH1A1HPGDHTTACHE
SCHEMBL2156012 0.69 CA2 (0.39) CA1CA2CA4CA7CA9
SCHEMBL2156052 0.68 CA1 (0.38) CA1CA2CA4CA7CA9
SCHEMBL13871409 0.66 EPHX2 (0.53) CA1CA2CA4CA7CA9
SCHEMBL11171650 0.66 CA1 (0.42) CA1CA2CA4CA7CA9
SCHEMBL2775772 0.64 KDM4E (0.63) CA2EPHX2KDM4EMEN1KMT2A
SCHEMBL26942243 0.64 PARP10 (0.54) EPHX2KDM4EMEN1KMT2AALDH1A1
SCHEMBL1552744 0.62 HPGD (0.39) CA1CA2CA7CA9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US disclosed
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US disclosed
EP-1888555-A2 SUBSTITUTED BENZO-CONDENSED CYCLOHEXANONE DERIVATIVES AND THE USE THEREOF FOR MEDICAMENT PRODUCTION Grünenthal GmbH (DE) 2008-02-20 EP disclosed
WO-2006122771-A2 SUBSTITUTED BENZO-CONDENSED CYCLOHEXANONE DERIVATIVES AND THE USE THEREOF FOR MEDICAMENT PRODUCTION Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production BCKDK, SYMPK, DHPS CA1 3722/4885CA2 2701/4885CA4 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.